Showing results (61-70 of 91) with videos related to
Sort By:
Pageof 10
Lancet (London, England)|May 11, 1991
Therapeutic effects of genetically engineered toxin (DAB486IL-2) in patient with chronic lymphocytic leukaemiaC F LeMaistre, M G Rosenblum, J M Reuben, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1993
Phase I trial of subcutaneous interleukin-6 in patients with advanced malignanciesJ Weber, J C Yang, S L Topalian, et al.Cancer Immunology, Immunotherapy : CII|January 1, 1991
Alteration in interactions between tumor-infiltrating lymphocytes and tumor cells in human melanomas after chemotherapy or immunotherapyK Itoh, K Hayakawa, M A Salmeron, et al.Cancer Treatment Reviews|June 1, 1989
Interleukin-2 alone and in combination with other cytokines in melanoma: the investigational approach at the University of Texas M.D. Anderson Cancer CenterD R Parkinson, M Talpaz, K H Lee, et al.Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|May 4, 1993
Hemodynamic effects of the administration of tumor-infiltrating lymphocytes to cancer patientsF M Marincola, J Balkissoon, D J Schwartzentruber, et al.JAMA|March 23, 1994
Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2S A Rosenberg, J C Yang, S L Topalian, et al.Cancer|August 15, 1995
The use of polyethylene glycol-modified interleukin-2 (PEG-IL-2) in the treatment of patients with metastatic renal cell carcinoma and melanoma. A phase I study and a randomized prospective study comparing IL-2 alone versus IL-2 combined with PEG-IL-2J C Yang, S L Topalian, D J Schwartzentruber, et al.In Vivo (Athens, Greece)|November 1, 1991
Immunological properties of melanoma tumor-infiltrating lymphocytes before and after IL-2-based biotherapiesK Itoh, C M Balch, J L Murray, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1990
Therapy of renal cell carcinoma with interleukin-2 and lymphokine-activated killer cells: phase II experience with a hybrid bolus and continuous infusion interleukin-2 regimenD R Parkinson, R I Fisher, A A Rayner, et al.Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|January 1, 1994
A phase II clinical trial of interleukin-2 and lymphokine-activated killer cells in advanced colorectal carcinomaM J Hawkins, M B Atkins, J P Dutcher, et al.Pageof 10